We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Electric Sensor Detects DNA for Disease Diagnosis

By LabMedica International staff writers
Posted on 01 Sep 2009
A newly developed electrical DNA biosensor will help to characterize pathogens and measure mRNA levels during expression profiling. More...
It will be suitable for point-of-care (POC) diagnosis and criminal investigations.

Scientists in Singapore developed the new electronic sensor that will offer a faster, less expensive, and more practical alternative to tests now used to detect DNA. The new lab-on-a-chip test will lead to wider, more convenient use of DNA testing.

Zhiqiang Gao, Ph.D., at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) and colleagues developed a nanogap sensor. They used a pair of micro-sized metal electrodes separated by a nanogap, 1/50,000 the width of a human hair, in combination with special chemical probes to capture tiny segments of DNA. The newly formed circuit then translated the presence of DNA into an electrical signal that that was measured by a computer. In laboratory tests, the sensor showed excellent sensitivity at detecting trace amounts of human DNA.

Another feature of the biosensor was its ability to capture DNA strands more effectively. The two surfaces of the sensor were coated with a chemically treated capture probe solution through an electrochemical technique specially developed by IBN. This allowed DNA strands to stick more easily to the sensor, resulting in a faster and more accurate analysis.

Current methods for detecting DNA use the polymerase chain reaction (PCR), which amplifies trace amounts of DNA, making it easier to detect the genetic material. The amplification step is one of the reasons why PCR tests can be expensive, cumbersome, and imprecise. The newly developed biosensor should eliminate the need for DNA amplification altogether.

"This new biosensor holds significant promise to speed up on-going efforts in the detection and diagnosis of debilitating diseases such as cancer, cardiovascular problems, and infectious viruses. We aim to make healthcare accessible to the masses with early disease diagnosis as the critical driving force behind the research we undertake here at IBN," said Jackie Y. Ying, Ph.D., executive director of IBN.

The study was published in the September 2, 2009, issue of the Journal of the American Chemical Society.

Related Links:

Institute of Bioengineering and Nanotechnology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.